Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study
- PMID: 12446534
- PMCID: PMC135490
- DOI: 10.1136/bmj.325.7374.1199
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study
Abstract
Objectives: An association between use of cannabis in adolescence and subsequent risk of schizophrenia was previously reported in a follow up of Swedish conscripts. Arguments were raised that this association may be due to use of drugs other than cannabis and that personality traits may have confounded results. We performed a further analysis of this cohort to address these uncertainties while extending the follow up period to identify additional cases.
Design: Historical cohort study.
Setting: 1969-70 survey of Swedish conscripts (>97% of the country's male population aged 18-20).
Participants: 50 087 subjects: data were available on self reported use of cannabis and other drugs, and on several social and psychological characteristics.
Main outcome measures: Admissions to hospital for ICD-8/9 schizophrenia and other psychoses, as determined by record linkage.
Results: Cannabis was associated with an increased risk of developing schizophrenia in a dose dependent fashion both for subjects who had ever used cannabis (adjusted odds ratio for linear trend of increasing frequency 1.2, 95% confidence interval 1.1 to 1.4, P<0.001), and for subjects who had used only cannabis and no other drugs (adjusted odds ratio for linear trend 1.3, 1.1 to 1.5, P<0.015). The adjusted odds ratio for using cannabis >50 times was 6.7 (2.1 to 21.7) in the cannabis only group. Similar results were obtained when analysis was restricted to subjects developing schizophrenia after five years after conscription, to exclude prodromal cases.
Conclusions: Cannabis use is associated with an increased risk of developing schizophrenia, consistent with a causal relation. This association is not explained by use of other psychoactive drugs or personality traits relating to social integration.
Comment in
-
Cannabis and mental health.BMJ. 2002 Nov 23;325(7374):1183-4. doi: 10.1136/bmj.325.7374.1183. BMJ. 2002. PMID: 12446510 Free PMC article. No abstract available.
Similar articles
-
Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County.Acta Psychiatr Scand. 1989 May;79(5):505-10. doi: 10.1111/j.1600-0447.1989.tb10296.x. Acta Psychiatr Scand. 1989. PMID: 2787581
-
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.Lancet. 1987 Dec 26;2(8574):1483-6. doi: 10.1016/s0140-6736(87)92620-1. Lancet. 1987. PMID: 2892048
-
The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study.Psychol Med. 2015 Jan;45(2):407-14. doi: 10.1017/S0033291714001524. Epub 2014 Jul 3. Psychol Med. 2015. PMID: 24990397 Free PMC article.
-
[Cannabis and psychosis].Ugeskr Laeger. 2006 Nov 6;168(45):3896-8. Ugeskr Laeger. 2006. PMID: 17118250 Review. Danish.
-
Cannabis consumption and psychosis or schizophrenia development.Int J Soc Psychiatry. 2018 Nov;64(7):690-704. doi: 10.1177/0020764018801690. Int J Soc Psychiatry. 2018. PMID: 30442059 Review.
Cited by
-
The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.Biol Psychiatry. 2016 Apr 1;79(7):595-603. doi: 10.1016/j.biopsych.2015.06.015. Epub 2015 Jun 19. Biol Psychiatry. 2016. PMID: 26210060 Free PMC article. Review.
-
ABC Schizophrenia study: an overview of results since 1996.Soc Psychiatry Psychiatr Epidemiol. 2013 Jul;48(7):1021-31. doi: 10.1007/s00127-013-0700-4. Epub 2013 May 5. Soc Psychiatry Psychiatr Epidemiol. 2013. PMID: 23644725
-
Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use.Schizophr Res Treatment. 2011;2011:501726. doi: 10.1155/2011/501726. Epub 2010 Jul 27. Schizophr Res Treatment. 2011. PMID: 22937266 Free PMC article.
-
Cannabis and mental health.BMJ. 2002 Nov 23;325(7374):1183-4. doi: 10.1136/bmj.325.7374.1183. BMJ. 2002. PMID: 12446510 Free PMC article. No abstract available.
-
Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat.Psychopharmacology (Berl). 2004 Dec;177(1-2):141-50. doi: 10.1007/s00213-004-1953-0. Epub 2004 Jul 29. Psychopharmacology (Berl). 2004. PMID: 15290005
References
-
- Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry. 1993;163:141–149. - PubMed
-
- Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use. Canberra: Australian Government Publishing Service; 1994.
-
- Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178:116–122. - PubMed
-
- Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2:1483–1486. - PubMed
-
- Johnson BA, Smith BL, Taylor P. Cannabis and schizophrenia. Lancet. 1988;1:592–593. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical